Last quarter (Q2 2022), Biodexa Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Biodexa Pharmaceuticals's net income was $―. See Biodexa Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ ―	$ 381.00K	$ 699.00K	$ 578.00K	$ 343.00K	$ 312.00K
Cost of Revenue	$ ―	$ ―	$ ―	$ 4.65M	$ 6.07M	$ 7.84M
Gross Profit	$ ―	$ 381.00K	$ 699.00K	$ -4.08M	$ -5.72M	$ -7.53M
Operating Expense	$ ―	$ 8.41M	$ 9.65M	$ 2.92M	$ 4.95M	$ 3.79M
Operating Income	$ ―	$ -8.03M	$ -8.95M	$ -7.00M	$ -10.67M	$ -11.32M
Net Non Operating Interest Income Expense	$ ―	$ 456.00K	$ 415.00K	$ 44.00K	$ 33.00K	$ 89.00K
Other Income Expense	$ ―	$ -14.00K	$ -22.00K	$ ―	$ ―	$ ―
Pretax Income	$ ―	$ -7.49M	$ -8.49M	$ -6.11M	$ -23.47M	$ -10.92M
Tax Provision	$ ―	$ -406.00K	$ 832.00K	$ -646.00K	$ -1.28M	$ -1.78M
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -7.08M	$ -9.32M	$ -5.46M	$ -22.19M	$ -10.09M
Basic EPS	$ ―	$ ―	$ ―	$ -1.40	$ -10.40	$ -220.00
Diluted EPS	$ ―	$ ―	$ ―	$ -1.40	$ -10.40	$ -220.00
Basic Average Shares	$ ―	$ ―	$ ―	$ 4.03M	$ 2.14M	$ 916.53K
Diluted Average Shares	$ ―	$ ―	$ ―	$ 4.03M	$ 2.14M	$ 45.83K
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ 8.41M	$ 9.65M	$ -7.58M	$ -11.01M	$ -11.63M
Net Income From Continuing And Discontinued Operation	$ ―	$ -7.08M	$ -9.32M	$ -5.46M	$ -22.19M	$ -10.09M
Normalized Income	$ ―	$ -7.89M	$ -6.88M	$ -6.75M	$ 384.00K	$ -9.61M
Interest Expense	$ ―	$ ―	$ ―	$ 44.00K	$ 34.00K	$ 97.00K
EBIT	$ ―	$ -7.44M	$ -8.44M	$ -6.06M	$ -23.44M	$ -11.77M
EBITDA	$ ―	$ -7.16M	$ -8.09M	$ -5.66M	$ -22.22M	$ -11.77M

Currency in USD

Biodexa Pharmaceuticals Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing